Report overview
Dihydropyridine (DHP) calcium channel blockers are derived from the molecule?dihydropyridine?and often used to reduce systemic vascular resistance and arterial pressure. Sometimes when they are used to treat?angina, the vasodilation and hypotension can lead to reflex?tachycardia, which can be detrimental for patients with?ischemicsymptoms because of the resulting increase in?myocardial?oxygen demand. Dihydropyridine calcium channel blockers can worsen?proteinuria?in patients with?nephropathy.
This report aims to provide a comprehensive presentation of the global market for Dihydropyridine Calcium Channel Blocker, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dihydropyridine Calcium Channel Blocker. This report contains market size and forecasts of Dihydropyridine Calcium Channel Blocker in global, including the following market information:
Global Dihydropyridine Calcium Channel Blocker Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Dihydropyridine Calcium Channel Blocker Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Dihydropyridine Calcium Channel Blocker companies in 2022 (%)
The global Dihydropyridine Calcium Channel Blocker market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Norvasc Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Dihydropyridine Calcium Channel Blocker include Pfizer, AstraZeneca, Abbott, Novartis, Sanofi, Sine Promod, Desano, Kang Lisheng Pharma and Guo Guang Pharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Dihydropyridine Calcium Channel Blocker manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dihydropyridine Calcium Channel Blocker Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dihydropyridine Calcium Channel Blocker Market Segment Percentages, by Type, 2022 (%)
Norvasc
Plendil
DynaCirc
Cardene
Others
Global Dihydropyridine Calcium Channel Blocker Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dihydropyridine Calcium Channel Blocker Market Segment Percentages, by Application, 2022 (%)
Hypertension
Coronary Artery Disease
Arrhythmia
Cardiomyopathy
Others
Global Dihydropyridine Calcium Channel Blocker Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Dihydropyridine Calcium Channel Blocker Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dihydropyridine Calcium Channel Blocker revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Dihydropyridine Calcium Channel Blocker revenues share in global market, 2022 (%)
Key companies Dihydropyridine Calcium Channel Blocker sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Dihydropyridine Calcium Channel Blocker sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
AstraZeneca
Abbott
Novartis
Sanofi
Sine Promod
Desano
Kang Lisheng Pharma
Guo Guang Pharma
Baiyunshan Pharma
Dawnrays
Outline of Major Chapters:
Chapter 1: Introduces the definition of Dihydropyridine Calcium Channel Blocker, market overview.
Chapter 2: Global Dihydropyridine Calcium Channel Blocker market size in revenue and volume.
Chapter 3: Detailed analysis of Dihydropyridine Calcium Channel Blocker manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dihydropyridine Calcium Channel Blocker in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Dihydropyridine Calcium Channel Blocker capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
